Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab
ErbB2 is an important oncogenic protein involved in carcinogenesis of, among others, breast, gastric, and ovarian carcinoma. Over-expression of ErbB2 is found in almost 20% of breast cancers, and this results in proliferative and anti-apoptotic signalling. ErbB2 is therefore an important treatment t...
Saved in:
Main Authors: | Juliana Bentes Hughes (Author), Marianne Skeie Rødland (Author), Max Hasmann (Author), Inger Helene Madshus (Author), Espen Stang (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2012-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab
by: Laure Thouvenin, et al.
Published: (2021) -
Development and validation of an LC-MS/MS method for simultaneous quantification of co-administered trastuzumab and pertuzumab
by: Sandor Schokker, et al.
Published: (2020) -
[Translated article] Cutaneous Apocrine Adenocarcinoma of the Groin With Extramammary Paget Disease: Response to Dual HER2 Blockade With Trastuzumab and Pertuzumab
by: J. Sola-Ortigosa, et al.
Published: (2022) -
Precision medicine and personalized breast cancer: combination pertuzumab therapy
by: Reynolds K, et al.
Published: (2014) -
Therapeutic Response Monitoring with <sup>89</sup>Zr-DFO-Pertuzumab in HER2-Positive and Trastuzumab-Resistant Breast Cancer Models
by: Minwoo Kang, et al.
Published: (2022)